Intrapleural use of tissue plasminogen activator and DNase in pleural infection
BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factor...
Principais autores: | Rahman, N, Maskell, N, West, A, Teoh, R, Arnold, A, Mackinlay, C, Peckham, D, Davies, C, Ali, N, Kinnear, W, Bentley, A, Kahan, B, Wrightson, J, Davies, H, Hooper, C, Lee, Y, Hedley, E, Crosthwaite, N, Choo, L, Helm, E, Gleeson, F, Nunn, A, Davies, R |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2011
|
Registros relacionados
-
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
por: Rahman, N, et al.
Publicado em: (2011) -
PRIMARY RESULT OF THE SECOND MULTICENTRE INTRAPLEURAL SEPSIS (MIST2) TRIAL; RANDOMISED TRIAL OF INTRAPLEURAL TPA AND DNASE IN PLEURAL INFECTION
por: Rahman, N, et al.
Publicado em: (2009) -
The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
por: Kanellakis, N, et al.
Publicado em: (2018) -
Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
por: Kanellakis, N, et al.
Publicado em: (2019) -
Intrapleural streptokinase for pleural infection.
por: Maskell, N, et al.
Publicado em: (2006)